Since the promising article on the 4-drug 5-FU led FOLFIRINOX regimen for metastatic pancreatic cancer per the May 12, 2011 article in the New England Journal of Medicine, this treatment approach has emerged as a solid first-line option. In the ensuing months there have been a number of studies exploring further options with this drug combination, including for other stages of cancer of the pancreas.
Now comes interesting research by Wahba and El-Hadaad of Mansoura University, Egypt as published in the September issue of the Journal of Gastrointestinal Cancer looking at a somewhat truncated version of this regimen in patients whose advanced pancreatic cancer showed progression after treatment with gemcitabine.
In a phase 2 clinical trial, the authors treated thirty such patients with a regimen that included 5-FU (fluorouacil), folinic acid, and oxaliplatin (the FOLFIRINOX regimen without irinotecan) with tolerable (adjudged) side-effects and a median overall survival of 22 weeks, and a six-month survival rate of 30%. They conclude that this regimen is active and in need of further study.
We concur. Very interesting work – that would benefit by follow-up research.
Dale O’Brien, MD